Compare JPM & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JPM | MRK |
|---|---|---|
| Founded | 1799 | 2000 |
| Country | United States | United States |
| Employees | 320079 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 900.8B | 317.8B |
| IPO Year | N/A | 1995 |
| Metric | JPM | MRK |
|---|---|---|
| Price | $358.11 | $128.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 17 |
| Target Price | ★ $331.93 | $125.59 |
| AVG Volume (30 Days) | ★ 7.4M | 6.4M |
| Earning Date | 04-14-2026 | 04-30-2026 |
| Dividend Yield | 1.94% | ★ 3.06% |
| EPS Growth | N/A | ★ 8.01 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $65,011,000,000.00 |
| Revenue This Year | $18.51 | $3.61 |
| Revenue Next Year | $4.11 | $5.41 |
| P/E Ratio | $15.42 | ★ N/A |
| Revenue Growth | N/A | ★ 1.31 |
| 52 Week Low | $279.10 | $77.58 |
| 52 Week High | $363.00 | $135.05 |
| Indicator | JPM | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 62.20 | 53.56 |
| Support Level | $323.83 | $112.68 |
| Resistance Level | N/A | $131.02 |
| Average True Range (ATR) | 6.65 | 3.10 |
| MACD | -0.04 | -0.41 |
| Stochastic Oscillator | 73.93 | 38.75 |
JPMorgan is a leading global financial services firm with operations in 66 countries and over 318,000 employees as of year-end 2025. Under the JPMorgan brands, the bank holding company boasts a $4.9 trillion balance sheet and $2.68 trillion in deposits, as of March 2026. The firm generates its revenue across three core operating segments: consumer and community banking, the commercial and investment bank, and asset and wealth management. It maintains the top global ranking in investment banking fees with an 8.4% market share, serves millions of consumers through its network of over 5,000 US branches, and manages over $7.1 trillion in client assets within its wealth and asset management franchise.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).